About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker BLCO · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Aug 12, 2026enVista Envy™ hydrophobic acrylic intraocular lens (IOL), e…
Lens, multifocal intraocular
BLCO
Bausch & Lomb, Inc.
Device approval (PMA), supplement
Special (Immediate Track)
P240005 ↗
May 15, 2026Stellaris Elite™ vision enhancement system; Posterior and C…BLCO
Bausch and Lomb
Device clearance (510(k))
Special
K261264 ↗
Mar 25, 2026Stellaris Elite™ vision enhancement system (BL11145, BL1445…BLCO
Bausch and Lomb, Incorporated
Device clearance (510(k))
Traditional
K252052 ↗
Jan 20, 2026ZIRGAN
GANCICLOVIR
BLCO
Bausch and Lomb
New drug (NDA), supplement
Labeling
NDA022211 ↗
Oct 21, 2025MIEBO
PERFLUOROHEXYLOCTANE
BLCO
Bausch and Lomb Inc
New drug (NDA), supplement
Labeling
NDA216675 ↗
Jul 30, 2025enVista Envy™ hydrophobic acrylic intraocular lens (IOL), e…
Lens, multifocal intraocular
BLCO
Bausch & Lomb, Inc.
Device approval (PMA), supplement
135 Review Track For 30-Day Notice
P240005 ↗
Jul 1, 2025NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
BLCO
Bausch and Lomb Inc
Generic (ANDA), supplement
Labeling
ANDA064065 ↗
Jul 1, 2025NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
BLCO
Bausch and Lomb Inc
Generic (ANDA), supplement
Labeling
ANDA064065 ↗
May 22, 2025XIPERE
TRIAMCINOLONE ACETONIDE
BLCO
Bausch and Lomb Inc
New drug (NDA), supplement
Labeling
NDA211950 ↗
Apr 8, 2025SofLens® Toric (alphafilcon A) Visibility Tinted Contact Le…BLCO
Bausch & Lomb, Inc.
Device approval (PMA), supplement
Real-Time Process
P960022 ↗
Apr 4, 2025RETISERT
FLUOCINOLONE ACETONIDE
BLCO
Bausch and Lomb
New drug (NDA), supplement
Labeling
NDA021737 ↗
Letter or label ↗
Feb 20, 2025Boston Orthokeratology (oprifocon A) Shaping lens for Overn…
Lens, contact, orthokeratology, overnight
BLCO
Bausch & Lomb
Device approval (PMA), supplement
Normal 180 Day Track
P010062 ↗
Feb 18, 2025BROMFENAC OPHTHALMIC SOLUTION, PROLENSA
BROMFENAC SODIUM
BLCO
Bausch and Lomb
New drug (NDA), supplement
Labeling
NDA203168 ↗
Jan 14, 2025enVista hydrophobic acrylic intraocular lens (IOL), enVista…
intraocular lens
BLCO
Bausch & Lomb, Inc.
Device approval (PMA), supplement
Real-Time Process
P910056 ↗
Jan 14, 2025enVista Envy hydrophobic acrylic intraocular lens (IOL), en…
Lens, multifocal intraocular
BLCO
Bausch & Lomb, Inc.
Device approval (PMA), supplement
Real-Time Process
P240005 ↗
Oct 10, 2024enVista Envy™ hydrophobic acrylic intraocular lens (IOL), e…
Lens, multifocal intraocular
BLCO
Bausch & Lomb, Inc.
Device approval (PMA)P240005 ↗
Oct 10, 2024EyeGility™ Inserter for Preloaded enVista IOLsBLCO
Bausch & Lomb, Incorporated
Device clearance (510(k))
Traditional
K242389 ↗
Aug 7, 2024OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION, EQUATE OLOPA…
OLOPATADINE HYDROCHLORIDE
BLCO
Bausch and Lomb Inc
Generic (ANDA), supplement
Manufacturing (CMC)
ANDA206046 ↗
Jul 29, 2024enVista hydrophobic acrylic IOL, enVista toric hydrophobic…
intraocular lens
BLCO
Bausch & Lomb, Inc.
Device approval (PMA), supplement
Normal 180 Day Track
P910056 ↗
Jul 26, 2024Stellaris Elite vision enhancement system (BL11145, BL14455…BLCO
Bausch and Lomb, Incorporated
Device clearance (510(k))
Traditional
K240169 ↗
Jul 25, 2024ISTALOL, TIMOLOL MALEATE
TIMOLOL MALEATE
BLCO
Bausch and Lomb
New drug (NDA), supplement
Labeling
NDA021516 ↗
Apr 25, 2024BRINZOLAMIDE
BRINZOLAMIDE
BLCO
Bausch and Lomb
Generic (ANDA), supplement
Labeling
ANDA204884 ↗
Apr 19, 2024LUMIFY PRESERVATIVE FREE EYE DROPS
BRIMONIDINE TARTRATE
BLCO
Bausch and Lomb Inc
New drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA218424 ↗
Apr 4, 2024XIIDRA
LIFITEGRAST
BLCO
Bausch and Lomb Inc
New drug (NDA), supplement
Manufacturing (CMC)
NDA208073 ↗
Mar 28, 2024Akreos Posterior Chamber Intraocular Lens
intraocular lens
BLCO
Bausch & Lomb, Inc.
Device approval (PMA), supplement
135 Review Track For 30-Day Notice
P060022 ↗
Feb 28, 2024LUMIFY REDNESS RELIEVER EYE DROPS
BRIMONIDINE TARTRATE
BLCO
Bausch and Lomb Inc
New drug (NDA), supplement
Labeling
NDA208144 ↗
Feb 26, 2024Stellaris Elite vision enhancement systemBLCO
Bausch and Lomb
Device clearance (510(k))
Traditional
K232084 ↗
Feb 22, 2024enVista® Hydrophobic Acrylic Intraocular Lens (IOL)
intraocular lens
BLCO
Bausch & Lomb, Inc.
Device approval (PMA), supplement
135 Review Track For 30-Day Notice
P910056 ↗
Jan 12, 2024VITRASE
HYALURONIDASE
BLCO
Bausch and Lomb
Biologic (BLA), supplement
Labeling
BLA021640 ↗
Dec 27, 2023LATANOPROST
LATANOPROST
BLCO
Bausch and Lomb
Generic (ANDA), supplement
Labeling
ANDA201006 ↗
Aug 21, 2023enVista Hydrophobic Acrylic Intraocular Lens
intraocular lens
BLCO
Bausch & Lomb, Inc.
Device approval (PMA), supplement
Normal 180 Day Track
P910056 ↗
Aug 14, 2023DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE
BLCO
Bausch and Lomb
Generic (ANDA), supplement
Labeling
ANDA090037 ↗
Aug 14, 2023DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE
BLCO
Bausch and Lomb
Generic (ANDA), supplement
Labeling
ANDA090037 ↗
Jul 21, 2023NEOMYCIN POLYMYXIN B SULFATES AND DEXAMETHASONE
DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
BLCO
Bausch and Lomb Inc
Generic (ANDA), supplement
Labeling
ANDA064135 ↗
Jul 21, 2023TOBRAMYCIN AND DEXAMETHASONE
DEXAMETHASONE; TOBRAMYCIN
BLCO
Bausch and Lomb Inc
Generic (ANDA), supplement
Labeling
ANDA064134 ↗
Jul 21, 2023TOBRAMYCIN AND DEXAMETHASONE
DEXAMETHASONE; TOBRAMYCIN
BLCO
Bausch and Lomb Inc
Generic (ANDA), supplement
Labeling
ANDA064134 ↗
Jun 22, 2023Amvisc and Amvisc Plus Ophthalmic Viscosurgical Device (OVD)
AID, SURGICAL, VISCOELASTIC
BLCO
Bausch & Lomb, Inc.
Device approval (PMA), supplement
135 Review Track For 30-Day Notice
P810025 ↗
Jun 22, 2023LEVOBUNOLOL HYDROCHLORIDE
LEVOBUNOLOL HYDROCHLORIDE
BLCO
Bausch and Lomb Inc
Generic (ANDA), supplement
Labeling
ANDA074326 ↗
Jun 22, 2023LEVOBUNOLOL HYDROCHLORIDE
LEVOBUNOLOL HYDROCHLORIDE
BLCO
Bausch and Lomb Inc
Generic (ANDA), supplement
Labeling
ANDA074326 ↗
May 18, 2023MIEBO
PERFLUOROHEXYLOCTANE
BLCO
Bausch and Lomb Inc
New drug (NDA)
Type 1 - New Molecular Entity
NDA216675 ↗
May 2, 2023LUMIFY REDNESS RELIEVER EYE DROPS
BRIMONIDINE TARTRATE
BLCO
Bausch and Lomb Inc
New drug (NDA), supplement
Manufacturing (CMC)
NDA208144 ↗
Mar 8, 2023Bausch + Lomb (kalifilcon A) Soft (hydrophilic) Contact Len…BLCO
Bausch & Lomb, Incorporated
Device clearance (510(k))
Traditional
K220613 ↗
Dec 6, 2022Bausch + Lomb Preservative Free Lubricating and Rewetting D…BLCO
Bausch & Lomb, Incorporated
Device clearance (510(k))
Traditional
K222541 ↗
Sep 23, 2022EYE ALLERGY RELIEF, OPCON-A
NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE
BLCO
Bausch and Lomb
New drug (NDA), supplement
Labeling
NDA020065 ↗
Apr 20, 2022Soflens 38 (polymacon) Visibility Tinted Contact Lenses
Lenses, soft contact, extended wear
BLCO
Bausch & Lomb, Inc.
Device approval (PMA), supplement
Real-Time Process
N16895 ↗
Apr 8, 2022Trulign® Toric Posterior Chamber Intraocular Lens (IOL)
Lens, intraocular, accommodative
BLCO
Bausch & Lomb, Inc.
Device approval (PMA), supplement
Normal 180 Day Track No User Fee
P030002 ↗
Mar 18, 2022SILSOFT (ELASTOFILCON A) CONTACT LENSES
Lenses, soft contact, extended wear
BLCO
Bausch & Lomb, Inc.
Device approval (PMA), supplement
Normal 180 Day Track
P850068 ↗
Mar 15, 2022ATROPINE SULFATE
ATROPINE SULFATE
BLCO
Bausch and Lomb Inc
New drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA213581 ↗
Jan 24, 2022Eureka!™ Monthly (samfilcon A) Contact Lenses
Lenses, soft contact, extended wear
BLCO
Bausch and Lomb, Inc.
Device approval (PMA), supplement
Normal 180 Day Track No User Fee
P170035 ↗
Nov 29, 2021LUMIFY REDNESS RELIEVER EYE DROPS
BRIMONIDINE TARTRATE
BLCO
Bausch and Lomb Inc
New drug (NDA), supplement
Labeling
NDA208144 ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:42 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates